Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1973 1
2020 3
2022 2
2023 1
2024 4
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Dementia Risk in Parkinson Disease.
Gallagher J, Gochanour C, Caspell-Garcia C, Dobkin RD, Aarsland D, Alcalay RN, Barrett MJ, Chahine L, Chen-Plotkin AS, Coffey CS, Dahodwala N, Eberling JL, Espay AJ, Leverenz JB, Litvan I, Mamikonyan E, Morley J, Richard IH, Rosenthal L, Siderowf AD, Simuni T, York MK, Willis AW, Xie SX, Weintraub D; Parkinson's Progression Markers Initiative. Gallagher J, et al. Neurology. 2024 Sep 10;103(5):e209699. doi: 10.1212/WNL.0000000000209699. Epub 2024 Aug 7. Neurology. 2024. PMID: 39110916 Free PMC article.
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts.
Dam T, Pagano G, Brumm MC, Gochanour C, Poston KL, Weintraub D, Chahine LM, Coffey C, Tanner CM, Kopil CM, Xiao Y, Chowdhury S, Concha-Marambio L, DiBiaso P, Foroud T, Frasier M, Jennings D, Kieburtz K, Merchant K, Mollenhauer B, Montine TJ, Nudelman K, Seibyl J, Sherer T, Singleton A, Stephenson D, Stern M, Soto C, Tolosa E, Siderowf A, Dunn B, Simuni T, Marek K; Parkinson’s Progression Markers Initiative. Dam T, et al. NPJ Parkinsons Dis. 2024 Sep 27;10(1):178. doi: 10.1038/s41531-024-00789-w. NPJ Parkinsons Dis. 2024. PMID: 39333167 Free PMC article.
Neuronal α-Synuclein Disease Stage Progression over 5 Years.
Simuni T, Gochanour C, Nair AR, Brumm MC, Coffey C, Poston KL, Chahine LM, Weintraub D, Tanner CM, Gonzalez-Latapi P, Kopil CM, Xiao Y, Chowdhury S, Dam T, Pagano G, Stephenson D, Siderowf A, Dunn B, Marek K; NSD Working Group the Parkinson's Progression Markers Initiative. Simuni T, et al. Mov Disord. 2025 Jul;40(7):1318-1330. doi: 10.1002/mds.30191. Epub 2025 Apr 30. Mov Disord. 2025. PMID: 40302527 Free PMC article.
LRRK2-associated parkinsonism with and without in vivo evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterization.
Chahine LM, Lafontant DE, Choi SH, Iwaki H, Blauwendraat C, Singleton AB, Brumm MC, Alcalay RN, Merchant K, Nudelman KNH, Dagher A, Vo A, Tao Q, Venuto CS, Kieburtz K, Poston KL, Bressman S, Gonzalez-Latapi P, Avants B, Coffey C, Jennings D, Tolosa E, Siderowf A, Marek K, Simuni T; Parkinson’s Progression Markers Initiative. Chahine LM, et al. Brain Commun. 2025 Mar 6;7(2):fcaf103. doi: 10.1093/braincomms/fcaf103. eCollection 2025. Brain Commun. 2025. PMID: 40114783 Free PMC article.
Genetic analysis and natural history of Parkinson's disease due to the LRRK2 G2019S variant.
Kmiecik MJ, Micheletti S, Coker D, Heilbron K, Shi J, Stagaman K, Filshtein Sonmez T, Fontanillas P, Shringarpure S, Wetzel M, Rowbotham HM, Cannon P, Shelton JF, Hinds DA, Tung JY; 23andMe Research Team; Holmes MV, Aslibekyan S, Norcliffe-Kaufmann L. Kmiecik MJ, et al. Brain. 2024 Jun 3;147(6):1996-2008. doi: 10.1093/brain/awae073. Brain. 2024. PMID: 38804604 Free PMC article.
Evaluation of ATNPD Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.
Cousins KAQ, Irwin DJ, Tropea TF, Rhodes E, Phillips J, Chen-Plotkin AS, Brumm MC, Coffey CS, Kang JH, Simuni T, Foroud TM, Toga AW, Tanner CM, Kieburtz KD, Mollenhauer B, Galasko D, Hutten S, Weintraub D, Siderowf AD, Marek K, Poston KL, Shaw LM; Parkinson's Progression Markers Initiative. Cousins KAQ, et al. Neurology. 2024 Feb;102(4):e208033. doi: 10.1212/WNL.0000000000208033. Epub 2024 Feb 2. Neurology. 2024. PMID: 38306599 Free PMC article.
Recruitment for Remote Decentralized Studies in Parkinson's Disease.
Myers TL, Augustine EF, Baloga E, Daeschler M, Cannon P, Rowbotham H, Chanoff E; 23andMe Research Team; Jensen-Roberts S, Soto J, Holloway RG, Marras C, Tanner CM, Dorsey ER, Schneider RB. Myers TL, et al. J Parkinsons Dis. 2022;12(1):371-380. doi: 10.3233/JPD-212935. J Parkinsons Dis. 2022. PMID: 34744053 Free PMC article.
Stable two-year longitudinal clinical outcomes in LRRK2 G2019S non-manifest carriers in a remote nationwide study.
Barbosa W, Auinger P, Pawlik M, Hartman E, Sharma S, Valdovinos BY, Wilson R, Norcliffe-Kaufmann L, Rowbotham H, Alcalay RN, Biglan K, Kinel D, Tanner CM, Holloway RG, Dorsey ER, Schneider RB. Barbosa W, et al. Parkinsonism Relat Disord. 2025 Sep;138:107969. doi: 10.1016/j.parkreldis.2025.107969. Epub 2025 Jul 21. Parkinsonism Relat Disord. 2025. PMID: 40701123
Exercise knowledge, barriers and motivators among LRRK2 G2019S mutation carriers.
Schootemeijer S, Coker D, Shelton JF, Chanoff E, Rowbotham HM, Darweesh SKL; 23and Me Research Team; Bloem BR, Cannon P, de Vries NM. Schootemeijer S, et al. Parkinsonism Relat Disord. 2023 Aug;113:105497. doi: 10.1016/j.parkreldis.2023.105497. Epub 2023 Jul 12. Parkinsonism Relat Disord. 2023. PMID: 37441884 Free article.
15 results